PH12020500532A1 - Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin - Google Patents

Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin

Info

Publication number
PH12020500532A1
PH12020500532A1 PH12020500532A PH12020500532A PH12020500532A1 PH 12020500532 A1 PH12020500532 A1 PH 12020500532A1 PH 12020500532 A PH12020500532 A PH 12020500532A PH 12020500532 A PH12020500532 A PH 12020500532A PH 12020500532 A1 PH12020500532 A1 PH 12020500532A1
Authority
PH
Philippines
Prior art keywords
dapagliflozin
metformin
proline
pharmaceutical formulation
combined pharmaceutical
Prior art date
Application number
PH12020500532A
Other languages
English (en)
Inventor
Jung Hyun Cho
Hyung Seo Kim
Taek Kwan Kwon
Yong Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/KR2018/011004 external-priority patent/WO2019066359A2/ko
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PH12020500532A1 publication Critical patent/PH12020500532A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PH12020500532A 2017-09-29 2020-03-13 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin PH12020500532A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170126878 2017-09-29
KR1020180079614A KR102369679B1 (ko) 2017-09-29 2018-07-09 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
PCT/KR2018/011004 WO2019066359A2 (ko) 2017-09-29 2018-09-18 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제

Publications (1)

Publication Number Publication Date
PH12020500532A1 true PH12020500532A1 (en) 2021-03-15

Family

ID=66164346

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020500532A PH12020500532A1 (en) 2017-09-29 2020-03-13 Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin

Country Status (3)

Country Link
KR (1) KR102369679B1 (ko)
BR (1) BR112020006395A2 (ko)
PH (1) PH12020500532A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121599A (ko) * 2020-03-30 2021-10-08 한미약품 주식회사 시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US8535715B2 (en) 2009-11-13 2013-09-17 Bristol-Myers Squibb Company Bilayer tablet formulations
US8871264B2 (en) 2009-11-13 2014-10-28 Astrazeneca Ab Immediate release tablet formulations
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
TR201202948A2 (tr) * 2012-03-15 2012-07-23 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Dapagliflozin ve uzatılmış salınımlı metaformin içeren tablet formülasyonu.
KR101750690B1 (ko) * 2015-10-28 2017-06-27 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
CN106924208A (zh) 2015-12-30 2017-07-07 深圳翰宇药业股份有限公司 一种复方达格列净二甲双胍缓释片及其制备方法

Also Published As

Publication number Publication date
KR102369679B1 (ko) 2022-03-04
KR20190038283A (ko) 2019-04-08
BR112020006395A2 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
IL279040A (en) Pharmaceutical combination, the composition and preparation of a combination containing a glucokinase activator and a biguanide drug for hypoglycemia, a method of their preparation and use
PH12017501222A1 (en) Glucagon derivatives with improved stability
WO2014144130A3 (en) Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
PH12019502655A1 (en) Acylated insulin compound
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
JP2017502074A5 (ko)
RU2016114098A (ru) Новое производное аналога инсулина
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2018097570A3 (ko) 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
PH12020500532A1 (en) Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin
JOP20170040B1 (ar) مركب لخفض جلوكوز الدم
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
MX2020002312A (es) Farmaceutica combinada que comprende dapagliflozina l-prolina y metformina.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
WO2016126026A3 (ko) 당뇨병 치료 조성물 및 이의 용도
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
WO2014195900A3 (es) Composiciones farmacéuticas orales para uso en dislipidemias
EA201991190A1 (ru) Фармацевтический комплексный препарат, содержащий амлодипин, лозартан и розувастатин